Incremental Health Reform First: Medco Sees Growing Resistance Around Price Controls
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Snow suggests that resistance to proposals authorizing government price controls through a public insurance option could also bring down programs with broad support, such as expanded use of health IT.
You may also be interested in...
Public Plan Using Medicare Rates Would Face Major Push-Back, Insurers Say
Provider opposition to a public insurance plan basing payments on Medicare rates may be enough to derail the idea of a public option in a health reform package, two leading insurers suggested in recent financial calls
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.